<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="370595">
  <stage>Registered</stage>
  <submitdate>28/04/2016</submitdate>
  <approvaldate>4/05/2016</approvaldate>
  <actrnumber>ACTRN12616000577415</actrnumber>
  <trial_identification>
    <studytitle>Effects of testosterone on urea metabolism in men with hypogonadism</studytitle>
    <scientifictitle>Effects of testosterone on urea metabolism in men with hypogonadism</scientifictitle>
    <utrn>NA</utrn>
    <trialacronym>N/A</trialacronym>
    <secondaryid>None</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Hypogonadism</healthcondition>
    <conditioncode>
      <conditioncode1>Metabolic and Endocrine</conditioncode1>
      <conditioncode2>Other endocrine disorders</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Metabolic and Endocrine</conditioncode1>
      <conditioncode2>Other metabolic disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Participants are studied at baseline, and then after two weeks of transdermal testosterone (Testogel; Besins Healthcare Australia Pty Ltd, 10mg /g) administration on upper back/shoulders at a dose of 100 mg/day once daily in the morning. Adherence will be monitored by empty drug packet return.</interventions>
    <comparator>No control group</comparator>
    <control>Uncontrolled</control>
    <interventioncode>Treatment: Drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Urea metabolism, assessed by plasma urea turnover studies using stable isotopes</outcome>
      <timepoint>At baseline and 2 weeks post commencement of testosterone treatment.</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Protein metabolism by plasma leucine turnover studies using stable isotopes</outcome>
      <timepoint>At baseline and 2 weeks post commencement of testosterone treatment.</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>1.	Diagnosed hypogonadism;
2.	Adequate replacement of other hormones in case of hypopituitarism;
3.	Able to comprehend the requirements and procedures for the study and to provide 	informed consent before entering the study


</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>75</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Males</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>1.	Any acute condition or exacerbation of chronic conditions that in the investigators opinion would interfere with the trial visit schedule and procedures;
2.	Cancer, diabetes mellitus, immunosuppressive steroid therapy and chronic renal or hepatic illnesses;  
3.	People in existing dependent or unequal relationships with any member of the research team;
4.	People who may be involved in illegal activity;
5.	People highly dependent on medical care;
6.	Patients who had received an investigational new drug within the last 6 month;
7.	Patients with a cognitive impairment, an intellectual disability or a mental condition which interfere with the patient's ability to understand the requirements of the study;
8.	Inability to give written informed consent.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment>NA</concealment>
    <sequence>NA</sequence>
    <masking>Open (masking not used)</masking>
    <assignment>Single group</assignment>
    <designfeatures>NA</designfeatures>
    <endpoint>Efficacy</endpoint>
    <statisticalmethods>Standard descriptive and statistical modelling approaches will be employed to analyse the data. Specifically, the treatment effects will be analysed by paired t-tests. Regression analysis will be used to determine the correlations between urea production rates and other endpoint measures. Sample size was calculated from our previous published data on the effects of testosterone on protein metabolism using similar investigation methods and sample size of 8 was determined at 80% power at p&lt; 0.05 significance.
</statisticalmethods>
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry>False</patientregistry>
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 4</phase>
    <anticipatedstartdate />
    <actualstartdate>16/01/2015</actualstartdate>
    <anticipatedenddate />
    <actualenddate>20/11/2015</actualenddate>
    <samplesize>8</samplesize>
    <actualsamplesize>8</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW</recruitmentstate>
    <hospital>Blacktown Hospital - Blacktown</hospital>
    <postcode>2148 - Blacktown</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Government body</primarysponsortype>
    <primarysponsorname>Western Sydney Local Health District</primarysponsorname>
    <primarysponsoraddress>Westmead Hospital, Institute Road, Westmead NSW 2145</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>University</fundingtype>
      <fundingname>Western Sydney University</fundingname>
      <fundingaddress>Locked Bag 1797 
Penrith NSW 2751 
Australia</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname>None</sponsorname>
      <sponsoraddress>NA</sponsoraddress>
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Patients with diagnosed hypogonadism will be studied at baseline and then after 2 weeks of testosterone replacement initiation at usual therapeutic doses (10 g Testogel). The study will involve measurements of urea metabolism, and whole body protein breakdown and oxidation, and how much of the amino acids are being recycled for new protein synthesis. </summary>
    <trialwebsite>NA</trialwebsite>
    <publication>NA</publication>
    <ethicsreview>Approved</ethicsreview>
    <publicnotes>NA</publicnotes>
    <ethicscommitee>
      <ethicname>WSLHD Human Research Ethics Committee</ethicname>
      <ethicaddress>Westmead Hospital, Institute Rd, Westmead NSW 2145</ethicaddress>
      <ethicapprovaldate>4/12/2014</ethicapprovaldate>
      <hrec>HREC/14/WMEAD/138 (3973)</hrec>
      <ethicsubmitdate>4/06/2014</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Dr</title>
      <name>Vita Birzniece</name>
      <address>Blacktown Clinical School, School of Medicine
Western Sydney University, Locked Bag 1797,
Penrith NSW 2751 					
Australia
</address>
      <phone>+61298516059</phone>
      <fax>+61298516050</fax>
      <email>v.birzniece@westernsydney.edu.au</email>
      <country>Australia</country>
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Vita Birzniece</name>
      <address>Blacktown Clinical School, School of Medicine
Western Sydney University, Locked Bag 1797,
Penrith NSW 2751 					
Australia
</address>
      <phone>+61298516059</phone>
      <fax>+61298516050</fax>
      <email>v.birzniece@westernsydney.edu.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Vita Birzniece</name>
      <address>Blacktown Clinical School, School of Medicine
Western Sydney University, Locked Bag 1797,
Penrith NSW 2751 					
Australia
</address>
      <phone>+61298516059</phone>
      <fax>+61298516050</fax>
      <email>v.birzniece@westernsydney.edu.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Vita Birzniece</name>
      <address>Blacktown Clinical School, School of Medicine
Western Sydney University, Locked Bag 1797,
Penrith NSW 2751 					
Australia
</address>
      <phone>+61298516059</phone>
      <fax>+61298516050</fax>
      <email>v.birzniece@westernsydney.edu.au</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
  </contacts>
</ANZCTR_Trial>